BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
'These data from both clinical trials and real-world settings continue to strengthen the evidence that ORLADEYO is an effective and well-tolerated long-term prophylactic treatment for HAE. Importantly, patients report not only fewer and less severe attacks, but also meaningful improvements in daily functioning and emotional well-being. This contributes to the growing body of evidence supporting the use of ORLADEYO as a long-term prophylactic option for adolescents and adults living with HAE,' said Helen Thackray, chief research and development officer of BioCryst.
The following four studies were presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Glasgow, United Kingdom, from June 13 to 16, 2025.
Berotralstat Use Reduced Number of HAE Attacks Requiring Treatment or Professional Care in Pediatric Patients: Interim Results from APeX-P
The ongoing open-label APeX-P study is evaluating the pharmacokinetic, safety, and effectiveness of berotralstat in children aged 2 to 11 years with HAE. Patients were enrolled into four weight-based cohorts. Cohort 1 received a 150 mg capsule once daily; cohorts 2-4 received once-daily oral granule doses of 108 mg, 96 mg and 78 mg, respectively.
The median age was 8 years (range: 3–11), with disease onset typically between ages 2–6 years. All patients received standard of care (SOC) treatment for 12 weeks prior to the study.
Key results
Eighty-six percent reduction in attacks requiring professional care: attacks dropped from 22 during the 12-week SOC period to three following 12 weeks of berotralstat treatment
Early/rapid and sustained reduction in the rate of HAE attacks requiring on-demand treatment
Mean (SEM) adjusted monthly attack rate decreased from 1.28 (0.25) during SOC to 0.38 (0.13) from day one to week four of berotralstat treatment
Sustained reduction for up to 48 weeks of follow-up
Berotralstat was well tolerated across all cohorts; the most common treatment-emergent adverse events were nasopharyngitis, upper respiratory tract infection, and headache.
Assessment of the Effectiveness and Tolerability of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: Findings from the Berolife Study
The Berolife study is an open-label observational study in France which assessed the real-world tolerability and effectiveness of oral once-daily berotralstat (150 mg) in patients with HAE aged >12 years. A total of 82 patients were enrolled, with a mean (SD) age of 40.0 (17.5) years. The mean (SD) baseline attack rate was 1.1 (1.0) attacks per month (median: 0.83), based on the six months prior to enrollment.
Key results
Significant reduction in monthly HAE attacks was observed at six months (in patients with follow-up data (n=37))
Median monthly attack rate decreased from 1.0 to 0.44 attacks after six months of berotralstat treatment
Sustained reductions in attack frequency maintained at 12, 18, and 24 months
Berotralstat was well tolerated throughout the study period
Adverse events were consistent with previous clinical trial data
Impact of Berotralstat on Quality of Life in Patients with Hereditary Angioedema
This analysis assessed the impact of berotralstat on patient-reported quality of life (QoL) outcomes compared to placebo, using pooled data from previous Phase 3 APeX-2 and APeX-J clinical trials which showed that once-daily berotralstat 150 mg significantly reduced the frequency of HAE attacks. This QoL assessment was measured using the validated Angioedema Quality of Life Questionnaire (AE-QoL), which evaluates four key domains: functioning, fatigue/mood, fears/shame, and nutrition.
Key results
Significant improvements in AE-QoL total and domain scores were observed with berotralstat versus placebo at week 24
Benefits sustained through week 96, indicating lasting improvement in daily life
At week 24, 60 percent of patients receiving berotralstat achieved the Minimal Clinically Important Difference (MCID) in AE-QoL total score, compared to 52.4 percent in the placebo group
Over time, the proportion of patients reaching MCID increased in the berotralstat cohort, suggesting progressive and cumulative improvements in QoL alongside reductions in HAE attack frequency
Patients With HAE Report Positive Perceptions Following Berotralstat Treatment: Results from a Focus Group
This qualitative study explored patient experiences with HAE, including their care journey and perceptions of treatment with berotralstat. Focus groups were conducted to gain insight into the real-world impact of berotralstat on patients' daily lives. Seven patients from France, aged 20-70 years, participated in the focus groups. All had been treated with berotralstat for at least six months, with a median age at HAE diagnosis of 28 years. Prior to starting berotralstat, the majority of participants (71 percent) had switched from previous treatments due to long-term tolerability concerns and guidance from health authorities.
Key findings
Participants reported notable improvements in disease control, including reduced frequency and severity of HAE attacks
Minimal side effects were observed
Berotralstat was described as less burdensome and easier to incorporate into daily routines compared to previous therapies
Improved disease management was associated with reduced psychological distress and a greater sense of normalcy, contributing to enhanced quality of life
About ORLADEYO® (berotralstat)ORLADEYO® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.
U.S. Indication and Important Safety Information
INDICATIONORLADEYO® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.
Limitations of useThe safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation.
IMPORTANT SAFETY INFORMATIONAn increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent.
The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.
A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C).
Berotralstat is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein. P-gp inducers (eg, rifampin, St. John's wort) may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO.
ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO.
The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established.
There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.
To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information.
About BioCryst PharmaceuticalsBioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
Forward-Looking StatementsThis press release contains forward-looking statements, including statements relating to ORLADEYO safety, performance and effectiveness. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst's ability to successfully implement or maintain its commercialization plans for ORLADEYO; interim results of a clinical trial do not necessarily predict final results; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay, or withdraw market approval for products and product candidates; and BioCryst's ability to successfully manage its growth and compete effectively. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's forward-looking statements.
BCRXW
Contact:John Bluth+1 919 859 7910jbluth@biocryst.com
Niamh Lyons+353 87 7745000nlyons@biocryst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
I was 17 when my boyfriend pulled out chunks of my hair. His abuse still haunts me at 43
As I sit in the hairdresser's chair, she lifts some strands of hair to look at the condition, and I freeze. I can already feel beads of sweat starting to form on my back. She asks, 'Been a while since you've had it cut?' I nod. It's been 10 months. I say, 'I've got a sensitive scalp, so can you be careful while washing it, please?' What I don't tell the hairdresser is that I dread anyone touching my head because 25 years ago, the man I loved ripped chunks of hair out while he was throwing me down the stairs. All because I didn't tell him I was going on a night out. For years, I wouldn't set foot inside a salon without taking a beta blocker I was prescribed by my GP for situational anxiety. I grit my teeth as she lathers the shampoo, trying not to think of the sharp pain and tingling I was left with when he yanked my hair so hard that he left me with a bald spot. It has got easier to deal with my hair being touched by strangers, but I never expected painful memories to be triggered so long after the relationship had ended. According to the charity Safe Lives, two-thirds of domestic abuse survivors experience post-traumatic stress disorder (PTSD) – more than twice the rate experienced by soldiers in combat. New research from the University of Glasgow has found that women who experienced physical abuse in the context of domestic violence risk ongoing mental health disorders despite the exposure to domestic violence having ceased, on average, 27 years before assessment. I met Colin at work when I was 17, and he was 33 (which, to everyone except me, was a huge red flag). I thought I was wise beyond my years, and Colin was everything I was looking for in a mate: strong, funny, intelligent and charming. After a few months of working together, we shared our first kiss on the way home from after-work drinks. He showered me with affection and attention; when we weren't at work, he called and texted constantly, which was flattering at first. Our relationship escalated quickly, and we were living together within three months. It took about six months before Colin became violent, but in the meantime, he had begun to manipulate and control every aspect of my life in ways that were nearly imperceptible at the time. We shared a bank account, but I was scatty and kept 'losing' my debit card, so he persuaded me it would be easier for him to give me a weekly cash allowance. I now think Colin was hiding my card all along. We worked together, so we spent every waking moment in each other's company. He would subtly belittle me in front of colleagues, picking on my insecurities and reinforcing every negative thought I ever had about myself. He poisoned me against my family (who could sense early on that he was bad news), causing an estrangement that would take years to heal. When my friends invited me out, he would guilt me into staying home, often claiming to be unwell. Friends stopped reaching out, and I became increasingly reliant on Colin. As this was my first serious relationship, I had no frame of reference or clue that his behaviour was troubling. The first act of violence happened at Christmas. Colin was sick with the flu, and I'd decided to go to the office Christmas party on a whim without telling him. When I returned to our flat, I discovered I was locked out. I battered at the door, and when Colin opened it, I saw his face twisted into a shape I didn't recognise. He was drunk, and I knew immediately that he was going to hurt me. He hissed, 'You've been with another man, haven't you, you sl-t?' as he grabbed me by the hair and threw me down a short flight of stairs. I banged my head hard, and it took me a minute to get back on my feet. When I did, Colin was standing before me with a chunk of my hair in his hand. Sobbing, I told him, 'I was at the Christmas party, ask anyone in the office,' but he just kept calling me a sl-t. I staggered down the stairs and into the cold December night. I had no idea where to go, I wasn't speaking to my parents, I didn't have any friends I could call. I just sat at a bus stop and wept. After about an hour, I heard footsteps and saw Colin. I cowered, thinking he was going to hurt me, and he started crying. 'I'm so sorry, baby. I don't know what came over me. I am so scared you're going to leave me.' He knelt at my feet and begged for forgiveness, and I found myself comforting him, even after what he'd done to me. He was a master manipulator and lured me back with promises that he'd change, and it would never happen again. But it did. We lived together peacefully for months at a time, then, as soon as he'd drunk too much or had a hard day, the violent rage would return. I lived in hypervigilance, barely talking in case I said something that would trigger Colin's rage. I lived in shame, not telling anyone about the abuse because I believed what was happening to me was my fault. I drank heavily, sank into a deep depression and would often feel disappointed to wake up in the morning. People ask, 'Why didn't you leave?' and I did try. The main issue was that I had nowhere to go. Shelters were full, I still wasn't in a good place with my family, and I had no money. When I did pluck up the courage to leave at age 20, he threatened to take his own life unless I came back to him, another manipulation tactic. In the end, it took three aborted attempts before I left for good, after one final eruption of violence that left me physically scarred and fearing for my life. When I left, I told him if he ever contacted me again, I would phone the police, and he could see that I meant it. I arrived on my parents' doorstep with my life in two bin bags and my mental health in tatters. Leaving was the easy part. Living with what had happened to me was much harder. I lived in a state of near-permanent anxiety and had flashbacks at unexpected moments, like in the hairdresser's chair when my head jerked back as the brush found a tug in my hair. I was right back to that December night, cowering in fear, my scalp on fire. When I had a wisdom tooth extraction, I couldn't look at myself in the mirror for over a week because my swollen, bruised face reminded me of a previous attack. I tried to push the memories down and get on with my life. After some time by myself, I started dating again, but found myself not only distrusting the men I met, but also my instincts. I had initially fallen for what I thought was a great guy, who turned out to be anything but, and was worried I was a terrible judge of character. However, at 21, I met Ronnie, a sweet man who was gentle, kind and understanding. We were married within six months of meeting, much to the surprise of everyone who knew us. I rushed into marriage partly to draw a line under my past because this new relationship came with a new surname and a move to a different city. My husband encouraged me to seek therapy because he had grown up in an abusive household and knew the lasting impact domestic violence could have. I had six sessions of NHS therapy and was diagnosed with PTSD, but that short course of treatment didn't 'fix' me. The therapy brought up a lot of intense and painful emotions, and I felt like I'd never be able to move past what happened to me. I didn't sleep properly for weeks after therapy finished. I felt hopeless and withdrew from my husband and my family, calling in sick to work and spending my days locked in the house, scared to go outside. I began to drink quite heavily one afternoon, pulling all the booze out to the cupboards that I could find. I wanted the pain to go away, and I would do anything I could to make it stop. I started raiding the medicine cabinet for painkillers, popping two handfuls of paracetamol into my mouth and washing them down with wine. I wanted to die. At first, I felt relieved; my pain would soon be over. Then I thought of my family and the people who loved me. I couldn't face the thought of living any more, but I wasn't ready to leave them. I called my husband and told him what I'd done, and he rushed home from work to take me to the hospital, where I promptly threw up all over the waiting room. After some blood tests, the hospital discharged me with a number for the crisis team, whom I was to check in with for the next few weeks, and who encouraged me to be more open with loved ones about how I was feeling. I hadn't been honest about the extent of the abuse, even with my family, so I sat them down and explained how bad things had been, and why I had decided that death was preferable to living with the pain. They were shocked, but started to understand more about how that relationship had forever altered me. Sharing my story with them helped to unload some of the shame I had felt over the relationship. I thought I had deserved what had happened to me, that I had provoked Colin to behave like that, but it was never my fault. I went back to suppressing my pain, mainly by drinking too much. My marriage ended after three years, partly because I had a paranoid mistrust of my husband. Every time my husband did something nice, I felt there had to be an ulterior motive because Colin was never kind for no reason. I've worked hard to rebuild my life after abuse, but have struggled with romantic relationships. Giving so much space and energy to mistrusting and second-guessing a potential partner's every move was exhausting, and I knew I needed to take a break from dating. I haven't been in a long-term relationship since my mid-20s. However, I am open to dating in the future. I've attended therapy on and off for years and began seeing a regular therapist in 2022, who referred me for specialist trauma therapy called eye movement desensitisation and reprocessing (EMDR). Instead of talking in detail about a distressing issue, EMDR instead focuses on changing the emotions, thoughts or behaviours that result from a distressing experience. Change didn't happen overnight, but the trauma no longer affects me as viscerally as it once did. I thought I was doing much better, but then, last November, I found out Colin had died. You'd think I'd be relieved. It was over; he could never hurt me again. I made an emergency therapy appointment because I found that I was sad about his death. I couldn't understand why until the therapist explained I had spent a lot of our early sessions saying, 'If only he had changed, maybe we could have been happy,' but that was a fantasy. I could never have forced Colin to change; he had to decide to change on his own. Perhaps I was mourning a version of him that didn't exist. Since Colin's death, I feel like I've turned a corner, mainly because the monster who haunted my nightmares wouldn't be coming back to get me. I am taking care of myself a lot better now; I quit drinking eight years ago and am trying my best to shed the heavy weight of past abuse and rebuild trust in others. I'm dating again, but I'm not putting any pressure on myself to find 'the one'. My life revolves around my friends, family, and my dog, a three-year-old spaniel named Bonnie, who gives me a reason to get outside as much as possible, which massively benefits my mental health. Things are less fraught when I go for a haircut, thanks to deep breathing exercises and restricting my trips to the hairdresser to twice a year. I hope I'll get to a point where the pain of the past won't be my whole narrative but rather a line in a chapter of my life story. Perhaps one day I will even enjoy trips to the salon. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
6 hours ago
- Yahoo
Triangle hospitals are seeing an increase in snake bite cases this year
Extreme heat has plagued the Triangle for several days already this year. And as temperatures have risen, local emergency departments have reported an increase in visits from snake bite patients. Snakes become more active during spring and summer months, said Dr. Ben German, an emergency department physician at WakeMed. Humans do, too, and that's one of the reasons why more snake bites occur during warmer times of year. On really hot days, though, snakes become more nocturnal, and people spend time outdoors later in the afternoons and evening. 'Around dusk seems to be the prime time for snake bites as we get into this time of year, because again, the snakes and people are more active together, and it's harder to see them,' German said. Some of these bites may be attributed to copperheads. The brown, Hershey's Kiss-shaped patterned snakes are the most common venomous snakes Triangle residents are likely to come across, and are one of just a handful of venomous snakes that live in North Carolina. Copperhead bites are rarely fatal for humans, but they may need to be treated with antivenom. The News & Observer asked WakeMed, UNC Health and Duke Health about how many patients with snake bites have been treated at their emergency departments so far this year. So far this year, WakeMed has treated slightly more snake bite cases than the same period last year. ▪ From Jan. 1-July 6, WakeMed saw 59 patients with snake bites. Of those, 33 received antivenom. ▪ Over the same period in 2024, 55 people came to WakeMed Emergency Departments with a snake bite, and 31 of them were treated with antivenom. German said snake bite cases have generally increased yearly since he began working at WakeMed in 2006, but he attributed that to an increase in the number of people moving to the area. UNC Health emergency departments have treated 112 people for snake bites so far this year. The highest number of snake bite patients visited the facilities in May and June — 39 and 45, respectively. In some of these cases, copperheads were specifically named in the diagnosis. Compared to last year, UNC Health Emergency Departments have treated more patients with snake bites so far this year. ▪ From January 2024 through early July 2024, UNC Health Emergency Departments saw 90 snake bite patients, including 45 in July. ▪ Across emergency departments, UNC Health treated at least one person with a snake bite each month in 2024. In five months — May through September — UNC Health Emergency Departments saw at least 20 people with snake bites, system-wide. And during fall and winter months, fewer patients visited emergency departments with snake bites. Duke Health hospitals typically see more than 100 patients with snake bites each year, Duke Health said in an emailed statement Thursday, July 10. And the highest number of monthly cases usually falls during July. So far this season, Duke Health has treated 33 patients with snake bites at emergency departments at three facilities — Duke University Hospital, Duke Regional Hospital and Duke Raleigh Hospital. Of those 33 cases, 11 sought treatment at Duke Health emergency departments since Tuesday, June 17. German, the WakeMed emergency physician, recommended three tips to avoid snake bites during this time of year: ▪ Wear good shoes outside. Sneakers are better than sandals, but leather shoes that cover above the ankle will work best to protect against bites to feet and lower legs. ▪ Be aware of your surroundings. Don't reach under objects or into spaces that aren't visible. Be careful when picking up debris, especially sticks, branches and mulch, which hide venomous copperheads well. ▪ If you're walking, taking out the trash or are outside for another reason later in the day or early in the morning, bring a flashlight. Have a question about your community you'd like answered? Or maybe a tip or story idea you'd like to share? The service journalism teams at The News & Observer and The Charlotte Observer want to hear from you. If you have a question about the Charlotte area, send The Charlotte Observer team a question by submitting questions to this form. If you have a question about Raleigh or a Triangle area community, send The News & Observer team a question by submitting questions to this form. Do snake repellents keep snakes out of your NC yard? What experts say Snake in a drive-thru? Boa found coiled under window of Triangle McDonald's
Medscape
10 hours ago
- Medscape
Potential Practice-Changer in Cystectomy Care
A 30-day course of prophylactic antibiotics following robot-assisted radical cystectomy significantly reduces the incidence of urinary tract infections (UTIs) and related complications, researchers have found. However, experts urge caution in interpreting the findings due to methodological limitations of the study. The researchers, led by Ahmed A. Hussein, MD, PhD, of Roswell Park Comprehensive Cancer Center in Buffalo, New York, randomized 77 patients undergoing robot-assisted radical cystectomy to receive either standard postoperative care or a 30-day course of oral antibiotics — either trimethoprim/sulfamethoxazole or nitrofurantoin — starting at discharge. Ahmed A. Hussein, MD, PhD The primary endpoint was the occurrence of symptomatic UTIs within 90 days, defined by a positive urine culture (> 105 CFU/mL) and clinical symptoms such as fever or flank pain. Dramatic Reduction in UTIs, Costs None of the 37 patients in the antibiotic group developed a UTI within 90 days compared with 10 of 40 patients (25%) in the group who received standard care ( P < .001). The antibiotic group also experienced significantly fewer infectious complications within 90 days of the procedure or discharge (14% vs 43%; P = .006) and readmissions related to infection (5% vs 30%; P = .007). The number needed to treat to prevent one UTI was calculated at 4 (95% CI, 2.5-7.0). 'This is very significant, as infectious complications are the most common after cystectomy and the main reason for readmission within 30 days of surgery. To bring this down from 25% to 0% improves patient care and saves a lot of resources for a procedure that is known for significant morbidity and for a very vulnerable patient population,' said Hussein, whose group published their findings in the Journal of Urology . The approach led to significant savings. Hussein and his colleagues found the mean cost of care after the procedure fell by roughly $9000 in the antibiotic group ( P =.007), with total 90-day costs more than $8000 lower ( P = .022). This figure included expenditures associated with readmissions, any additional procedures, medications, and drains. No increase in adverse events or high-grade complications was observed in the antibiotic arm, the researchers reported. Hussein said he believed the cost savings are generalizable to other institutions and health systems. 'Radical cystectomy is a highly morbid procedure with significant rate of complications regardless of open or robotic approach. Infections remain very significant,' he said. 'While the choice of antibiotic may vary based on the local hospital antibiograms, we believe the approach — should be equally effective. We encourage all centers considering this approach to review their retrospective data and to determine the most appropriate antibiotic for their patient population,' he added. Editorial Perspective: Promising but Preliminary Nicholas H. Chakiryan, MD, from the Department of Urology, Oregon Health & Science University in Portland, Oregon, noted the lack of placebo control and blinding in the study may have introduced bias. 'If clinicians know a patient is on antibiotics, they may be less likely to diagnose a UTI,' he wrote in a commentary on the study. In a separate commentary, Luigi Nocera, MD, from ASST Spedali Civili in Brescia, and Alessandro Viti, MD, from Università Vita-Salute San Raffaele in Milan, both in Italy, echoed these concerns and highlighted the gender imbalance between groups. More women, who are generally at higher risk for UTIs, were in the arm that received standard care (35% vs 14%; P = .036). They also pointed to the exclusion of patients with renal dysfunction and the absence of long-term data on antimicrobial resistance. 'Although extended antibiotic prophylaxis following [robotic cystectomy] appears to significantly reduce infectious morbidity and healthcare costs, its routine adoption requires caution,' Nocera and Viti wrote. 'Future large-scale, blinded, placebo-controlled trials with proper stratification are essential to guide evidence-based clinical practice without undermining antibiotic stewardship principles.' Methodological Rigor and Limitations 'The study employed a robust definition of UTI, requiring both microbiological and clinical criteria, which strengthens its validity compared to prior studies that included asymptomatic bacteriuria,' Nocera and Viti wrote. All patients received intravenous ertapenem at anesthesia induction, and only 4% had ureteral stents. Compliance with the antibiotic regimen was high, with 68% of patients completing the full 30-day course. 'Before we designed the RCT [randomized controlled trial], we actually reviewed our retrospective data that were published in the Journal of Endourology ,' Hussein said. 'So this RCT was based on the sensitivities that our previous patient had, and therefore, we were expecting that these chosen antibiotics would work. There was really no significant difference among the two groups when it comes to adverse events.' Despite its limitations, the trial provides the highest level of evidence to date supporting extended antibiotic prophylaxis after cystectomy. 'This represents the highest quality data on the subject and is likely to change practice for many urologic oncologists, myself included,' Chakiryan wrote. Still, widespread adoption should await confirmation from larger, multicenter, placebo-controlled trials, he added. 'This study moves the needle,' he wrote, 'but we're not at the finish line yet.' The sources cited in this story reported having no relevant financial conflicts of interest.
